BI 113608

Drug Profile

BI 113608

Alternative Names: BI-113608

Latest Information Update: 11 Mar 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 01 May 2014 Boehringer Ingelheim completes a phase I trial in Healthy Asian & Caucasian volunteers in South Korea (NCT01922349)
  • 01 May 2014 Boehringer Ingelheim completes a phase I trial in Chronic obstructive pulmonary disease in Germany (NCT01958008)
  • 01 Oct 2013 Boehringer Ingelheim plans a phase I trial in Chronic obstructive pulmonary disease in Germany (NCT01958008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top